---
schema_version: "secwatch.filing_event.v1"
accession: "0001746473-23-000036"
form_type: "8-K"
ticker: "PLRX"
cik: "0001746473"
company_name: "PLIANT THERAPEUTICS, INC."
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T05:08:57.713179+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Pliant Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor at 2023 annual meeting

## Summary
- All three Class III director nominees (Coulie, Crowell, Bruhn) elected; Coulie received 48.3M for, 1.1M withhold.
- Non-binding say-on-pay proposal approved with 47.99M for, 1.38M against, 36k abstain.
- Ratification of Deloitte & Touche LLP as auditor for FY2023 passed with 54.81M for, 12.5k against.
- Broker non-votes totaled 5,432,103 shares on director election and say-on-pay.

## SEC filing metadata
- accession: 0001746473-23-000036
- form_type: 8-K
- ticker: PLRX
- cik: 0001746473
- company_name: PLIANT THERAPEUTICS, INC.
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000036/0001746473-23-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000036/plrx-20230607.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001746473-23-000036
- JSON: https://secwatch.observer/filing/0001746473-23-000036.json
- Plain text: https://secwatch.observer/filing/0001746473-23-000036.txt

## Key facts
- Shareholder Votes
  PLIANT THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-07 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-07
  source text: Proposal 3: The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm. The votes cast at the Annual Meeting were as follows: For Against Abstain 54,811,068 12,512 19,255
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000036/0001746473-23-000036-index.htm
- Shareholder Votes
  PLIANT THERAPEUTICS, INC. shareholders approved Election of Bernard Coulie, M.D., Ph.D., Gayle Crowell and Suzanne Bruhn, Ph.D. as Class III directors at the 2023-06-07 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-07
  source text: Proposal 1: The Company’s stockholders approved the election of the aforementioned Class III directors recommended for election at the Annual Meeting. The Company’s stockholders voted for the Class III directors as follows: Nominee For Withhold Bernard Coulie, M.D., Ph.D. 48,316,375 1,094,357 Gayle Crowell 39,771,872 9,638,860 Suzanne Bruhn, Ph.D. 39,735,738 9,674,994 The broker non-votes for Proposal 1 totaled 5,432,103 shares of common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000036/0001746473-23-000036-index.htm
- Shareholder Votes
  PLIANT THERAPEUTICS, INC. shareholders approved Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers at the 2023-06-07 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-07
  source text: Proposal 2: The Company’s stockholders approved, by non-binding advisory vote, the compensation of the Company’s named executive officers, as follows: For Against Abstain 47,994,590 1,379,942 36,200 The broker non-votes for Proposal 2 totaled 5,432,103 shares of common stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1746473/000174647323000036/0001746473-23-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.